Active Not Recruiting PHASE3 INTERVENTIONAL 2-arm NCT06662383

A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity (TRIUMPH-5)

A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Retatrutide Compared to Tirzepatide in Adults Who Have Obesity

Sponsor: Eli Lilly and Company

Conditions Obesity

Interventions Retatrutide Tirzepatide

Updated 7 times since 2024 Last updated: Apr 25, 2025 Started: Nov 1, 2024 Primary completion: Dec 31, 2026 Completion: Dec 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Obesity, this trial is ongoing. The trial is conducted by Eli Lilly and Company and has accumulated 7 data snapshots since 2024. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Active Not Recruiting PHASE3
May 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Apr 2025 — May 2025 [monthly]

Recruiting PHASE3
Mar 2025 — Apr 2025 [monthly]

Recruiting PHASE3
Jan 2025 — Mar 2025 [monthly]

Recruiting PHASE3

▶ Show 2 earlier versions

Dec 2024 — Jan 2025 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Nov 2024 — Dec 2024 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company

Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Aurora, United States , Baton Rouge, United States , Bay City, United States , Bialystok, Poland , Bridgeport, United States , Brownsville, United States , Buenos Aires, Argentina , Charlottesville, United States , Chattanooga, United States and 43 more locations